Recombinant Human Thrombopoietin

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Generic Name
Recombinant Human Thrombopoietin
DrugBank Accession Number
DB16364
Background

Recombinant human thrombopoietin is a full-length glycosylated cytokine produced by Chinese hamster ovary cells and is used to promote the generation of megakaryocytes and platelets.1,2 This drug is used in the treatment of thrombocytopenia.

Type
Biotech
Groups
Investigational
Synonyms
  • rhTPO
  • rHuTPO
External IDs
  • Recombinant Human Thrombopoietin

Pharmacology

Indication

Not Available

Pharmacology
Accelerate your drug discovery research with the industry’s only fully connected ADMET dataset, ideal for:
Machine Learning
Data Science
Drug Discovery
Accelerate your drug discovery research with our fully connected ADMET dataset
Learn more
Contraindications & Blackbox Warnings
Contraindications
Contraindications & Blackbox Warnings
With our commercial data, access important information on dangerous risks, contraindications, and adverse effects.
Learn more
Our Blackbox Warnings cover Risks, Contraindications, and Adverse Effects
Learn more
Pharmacodynamics

Not Available

Mechanism of action

Recombinant human thrombopoietin has similar biological functions as endogenous thrombopoietin.2 It activates the thrombopoietin receptor MPL.1 This therapy has potential roles in hematopoietic stem and progenitor cell regeneration and is currently being investigated against relapsed immune thrombocytopenia, hematopoietic injury, and acute severe thrombocytopenia in sepsis.

Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Medicalerrors
Reduce medical errors
and improve treatment outcomes with our comprehensive & structured data on drug adverse effects.
Learn more
Reduce medical errors & improve treatment outcomes with our adverse effects data
Learn more
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Not Available
Food Interactions
Not Available

Products

Products
Comprehensive & structured drug product info
From application numbers to product codes, connect different identifiers through our commercial datasets.
Learn more
Easily connect various identifiers back to our datasets
Learn more

Categories

Drug Categories
Not Available
Classification
Not classified
Affected organisms
Not Available

Chemical Identifiers

UNII
Not Available
CAS number
Not Available

References

General References
  1. Wang C, Zhang B, Wang S, Zhang J, Liu Y, Wang J, Fan Z, Lv Y, Zhang X, He L, Chen L, Xia H, Li Y, Pei X: Recombinant human thrombopoietin promotes hematopoietic reconstruction after severe whole body irradiation. Sci Rep. 2015 Sep 25;5:12993. doi: 10.1038/srep12993. [Article]
  2. Zhou Z, Feng T, Xie Y, Huang P, Xie H, Tian R, Qian B, Wang R: The effect of recombinant human thrombopoietin (rhTPO) on sepsis patients with acute severe thrombocytopenia: a study protocol for a multicentre randomised controlled trial (RESCUE trial). BMC Infect Dis. 2019 Sep 6;19(1):780. doi: 10.1186/s12879-019-4388-2. [Article]
Not Available

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
4CompletedTreatmentThrombocytopenia1
4RecruitingTreatmentChronic Liver Diseases (CLD) / Thrombocytopenia; Drugs1
4RecruitingTreatmentPrimary Immune Thrombocytopenia1
4RecruitingTreatmentThrombocytopenia1
4Unknown StatusTreatmentAllogeneic peripheral haematopoietic stem cell transplant / Delayed Platelet Engraftment / Myeloablative1
3CompletedPreventionSarcomas1
3CompletedTreatmentHematologic Diseases / Thrombocytopenia1
3CompletedTreatmentIdiopathic Thrombocytopenic Purpura / Purpura3
3CompletedTreatmentImmune Thrombocytopenia1
3CompletedTreatmentImmune Thrombocytopenia / Pregnant State1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
FormRouteStrength
Injection, solution15000 iu/1ml
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available

Drug created on December 17, 2020 22:51 / Updated on May 05, 2021 20:32